Deal set to close in Q2.
PRAC to review Uptravi after five deaths in France.
Biotech’s R&D operations will be spun off.
2017 could be a bumper year for M&A – but Trump’s price control threats dominate
Deal expected to be worth around $30 billion.
Reports suggest Sanofi could pay $30 billion for Swiss biotech.
Companies confirm takeover talks.
Could Swiss biotech finally be snapped up?